文献速递膀胱癌与上尿路尿路上皮癌

转移性尿路上皮癌的综合分子特征揭示基因组与转录组亚型

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
PubMed 文献 · Eur Urol · 2022-01-25

研究对116例计划接受姑息性系统治疗的转移性尿路上皮癌患者的转移灶新鲜冷冻活检组织进行全基因组DNA和RNA测序,识别出两种主要基因组亚型(GenS1占67%,APOBEC驱动;GenS2占24%,富含活性氧相关新发突变特征)和五种转录组亚型(管腔a和管腔b占40%、间质丰富型占24%、基底/鳞状占23%、非特指型占12%),并整合数据提出按转录组亚型及个体化的潜在治疗选择。

要点

  • 转移性尿路上皮癌存在两种主要基因组亚型:GenS1(67%)由APOBEC驱动,GenS2(24%)富含活性氧相关新发突变特征。
  • 转录组分析识别五种亚型:管腔a和管腔b(40%)、间质丰富型(24%)、基底/鳞状(23%)、非特指型(12%)。
  • 各转录组亚型在关键基因表达、显著突变基因、致癌通路活性和免疫细胞浸润方面存在差异。

核心结论

  • 转移性尿路上皮癌是一种异质性疾病,具有不同的分子亚型,并可为每种亚型确定可能的治疗靶点。

研究设计与样本

  • 研究对116例计划在临床试验(NCT01855477和NCT02925234)背景下接受姑息性系统治疗的转移性尿路上皮癌患者的转移灶新鲜冷冻活检组织进行全基因组DNA和RNA测序分析。

主要发现

  • 对突变特征进行层次聚类揭示两种主要基因组亚型:GenS1占67%,由APOBEC驱动;GenS2占24%,具有高比例的活性氧相关新发突变特征,推测为时钟样。
  • 显著突变基因在基因组亚型间无差异。
  • 转录组分析揭示五种转移性尿路上皮癌亚型:管腔a和管腔b占40%,间质丰富型占24%,基底/鳞状占23%,非特指型占12%。
  • 这些亚型在关键基因表达、显著突变基因、致癌通路活性和免疫细胞浸润方面存在差异。

关键数值与推荐

  • 基因组亚型:GenS1占67%,GenS2占24%。
  • 转录组亚型:管腔a和管腔b占40%,间质丰富型占24%,基底/鳞状占23%,非特指型占12%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent molecular characterization of primary urothelial carcinoma (UC) may guide future clinical decision-making. For metastatic UC (mUC), a comprehensive molecular characterization is still lacking. We analyzed whole-genome DNA and RNA sequencing data for fresh-frozen metastatic tumor biopsies from 116 mUC patients who were scheduled for palliative systemic treatment within the context of a clinical trial (NCT01855477 and NCT02925234). Hierarchical clustering for mutational signatures revealed two major genomic subtypes: GenS1 (67%), which was APOBEC-driven; and GenS2 (24%), which had a high fraction of de novo mutational signatures related to reactive oxygen species and is putatively clock-like. Significantly mutated genes (SMGs) did not differ between the genomic subtypes. Transcriptomic analysis revealed five mUC subtypes: luminal-a and luminal-b (40%), stroma-rich (24%), basal/squamous (23%), and a nonspecified subtype (12%). These subtypes differed regarding expression of key genes, SMGs, oncogenic pathway activity, and immune cell infiltration. We integrated the genomic and transcriptomic data to propose potential therapeutic options by transcriptomic subtype and for individual patients. This in-depth analysis of a large cohort of patients with mUC may serve as a reference for subtype-oriented and patient-specific research on the etiology of mUC and for novel drug development. PATIENT SUMMARY: We carried out an in-depth analysis of the molecular and genetic features of metastatic cancer involving the cells that line the urinary tract. We showed that this is a heterogeneous disease with different molecular subtypes and we identified possible targets for therapy for each subtype.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nakauma-González JA, Rijnders M, van Riet J, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol. 2022. PMID: 35086719. doi:10.1016/j.eururo.2022.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。